Cargando…

Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics

INTRODUCTION: In patients with SARS-CoV-2, innate immunity is playing a central role, depicted by hyperinflammation and longer lasting inflammatory response. Reliable inflammatory markers that cover both acute and long-lasting COVID-19 monitoring are still lacking. Thus, we investigated one specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Bizjak, Daniel Alexander, Stangl, Manfred, Börner, Nikolaus, Bösch, Florian, Durner, Joachim, Drunin, Gergana, Buhl, Jasmine-Leonike, Abendroth, Dietmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537769/
https://www.ncbi.nlm.nih.gov/pubmed/36211365
http://dx.doi.org/10.3389/fimmu.2022.1004545
_version_ 1784803276094439424
author Bizjak, Daniel Alexander
Stangl, Manfred
Börner, Nikolaus
Bösch, Florian
Durner, Joachim
Drunin, Gergana
Buhl, Jasmine-Leonike
Abendroth, Dietmar
author_facet Bizjak, Daniel Alexander
Stangl, Manfred
Börner, Nikolaus
Bösch, Florian
Durner, Joachim
Drunin, Gergana
Buhl, Jasmine-Leonike
Abendroth, Dietmar
author_sort Bizjak, Daniel Alexander
collection PubMed
description INTRODUCTION: In patients with SARS-CoV-2, innate immunity is playing a central role, depicted by hyperinflammation and longer lasting inflammatory response. Reliable inflammatory markers that cover both acute and long-lasting COVID-19 monitoring are still lacking. Thus, we investigated one specific inflammatory marker involved as one key player of the immune system, kynurenine (Kyn), and its use for diagnosis/detection of the Long-/Post-COVID syndrome in comparison to currently used markers in both serum and saliva samples. MATERIAL AND METHODS: The study compromised in total 151 inpatients with a SARS-CoV-2 infection hospitalized between 03/2020 and 09/2021. The group NC (normal controls) included blood bank donors (n=302, 144f/158m, mean age 47.1 ± 18.3 years (range 18-75)). Two further groups were generated based on Group A (n=85, 27f/58m, mean age 63.1 ± 18.3 years (range 19-90), acute admission to the hospital) and Group B (n=66, 22f/44m, mean age 66.6 ± 17.6 years (range 17-90), admitted either for weaning or for rehabilitation period due to Long-COVID symptoms/syndrome). Plasma concentrations of Kyn, C-Reactive Protein (CRP) and interleukin-6 (IL-6) were measured on admission. In Group B we determined Kyn 4 weeks after the negative PCR-test. In a subset of patients (n=11) concentrations of Kyn and CRP were measured in sera and saliva two, three and four months after dismission. We identified 12 patients with Post-COVID symptoms >20 weeks with still significant elevated Kyn-levels. RESULTS: Mean values for NC used as reference were 2.79 ± 0.61 µM, range 1.2-4.1 µM. On admission, patients showed significantly higher concentrations of Kyn compared to NC (p-values < 0.001). Kyn significantly correlated with IL-6 peak-values (r=0.411; p-values <0.001) and CRP (r=0.488, p-values<0.001). Kyn values in Group B (Long-/Post-COVID) showed still significant higher values (8.77 ± 1.72 µM, range 5.5-16.6 µM), whereas CRP values in Group B were in the normal range. CONCLUSION: Serum and saliva Kyn are reflecting the acute and long-term pathophysiology of the SARS-CoV-2 disease concerning the innate immune response and thus may serve a useful biomarker for diagnosis and monitoring both Long- and Post-COVID syndrome and its therapy.
format Online
Article
Text
id pubmed-9537769
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95377692022-10-08 Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics Bizjak, Daniel Alexander Stangl, Manfred Börner, Nikolaus Bösch, Florian Durner, Joachim Drunin, Gergana Buhl, Jasmine-Leonike Abendroth, Dietmar Front Immunol Immunology INTRODUCTION: In patients with SARS-CoV-2, innate immunity is playing a central role, depicted by hyperinflammation and longer lasting inflammatory response. Reliable inflammatory markers that cover both acute and long-lasting COVID-19 monitoring are still lacking. Thus, we investigated one specific inflammatory marker involved as one key player of the immune system, kynurenine (Kyn), and its use for diagnosis/detection of the Long-/Post-COVID syndrome in comparison to currently used markers in both serum and saliva samples. MATERIAL AND METHODS: The study compromised in total 151 inpatients with a SARS-CoV-2 infection hospitalized between 03/2020 and 09/2021. The group NC (normal controls) included blood bank donors (n=302, 144f/158m, mean age 47.1 ± 18.3 years (range 18-75)). Two further groups were generated based on Group A (n=85, 27f/58m, mean age 63.1 ± 18.3 years (range 19-90), acute admission to the hospital) and Group B (n=66, 22f/44m, mean age 66.6 ± 17.6 years (range 17-90), admitted either for weaning or for rehabilitation period due to Long-COVID symptoms/syndrome). Plasma concentrations of Kyn, C-Reactive Protein (CRP) and interleukin-6 (IL-6) were measured on admission. In Group B we determined Kyn 4 weeks after the negative PCR-test. In a subset of patients (n=11) concentrations of Kyn and CRP were measured in sera and saliva two, three and four months after dismission. We identified 12 patients with Post-COVID symptoms >20 weeks with still significant elevated Kyn-levels. RESULTS: Mean values for NC used as reference were 2.79 ± 0.61 µM, range 1.2-4.1 µM. On admission, patients showed significantly higher concentrations of Kyn compared to NC (p-values < 0.001). Kyn significantly correlated with IL-6 peak-values (r=0.411; p-values <0.001) and CRP (r=0.488, p-values<0.001). Kyn values in Group B (Long-/Post-COVID) showed still significant higher values (8.77 ± 1.72 µM, range 5.5-16.6 µM), whereas CRP values in Group B were in the normal range. CONCLUSION: Serum and saliva Kyn are reflecting the acute and long-term pathophysiology of the SARS-CoV-2 disease concerning the innate immune response and thus may serve a useful biomarker for diagnosis and monitoring both Long- and Post-COVID syndrome and its therapy. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9537769/ /pubmed/36211365 http://dx.doi.org/10.3389/fimmu.2022.1004545 Text en Copyright © 2022 Bizjak, Stangl, Börner, Bösch, Durner, Drunin, Buhl and Abendroth https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Bizjak, Daniel Alexander
Stangl, Manfred
Börner, Nikolaus
Bösch, Florian
Durner, Joachim
Drunin, Gergana
Buhl, Jasmine-Leonike
Abendroth, Dietmar
Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics
title Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics
title_full Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics
title_fullStr Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics
title_full_unstemmed Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics
title_short Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics
title_sort kynurenine serves as useful biomarker in acute, long- and post-covid-19 diagnostics
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537769/
https://www.ncbi.nlm.nih.gov/pubmed/36211365
http://dx.doi.org/10.3389/fimmu.2022.1004545
work_keys_str_mv AT bizjakdanielalexander kynurenineservesasusefulbiomarkerinacutelongandpostcovid19diagnostics
AT stanglmanfred kynurenineservesasusefulbiomarkerinacutelongandpostcovid19diagnostics
AT bornernikolaus kynurenineservesasusefulbiomarkerinacutelongandpostcovid19diagnostics
AT boschflorian kynurenineservesasusefulbiomarkerinacutelongandpostcovid19diagnostics
AT durnerjoachim kynurenineservesasusefulbiomarkerinacutelongandpostcovid19diagnostics
AT druningergana kynurenineservesasusefulbiomarkerinacutelongandpostcovid19diagnostics
AT buhljasmineleonike kynurenineservesasusefulbiomarkerinacutelongandpostcovid19diagnostics
AT abendrothdietmar kynurenineservesasusefulbiomarkerinacutelongandpostcovid19diagnostics